MEETINGS - The British Standards Institution (BSI) Product Certification Division is holding the following seminars (UK) November - December 1995:
This article was originally published in Clinica
The British Standards Institution (BSI) Product Certification Division is holding three seminars later this year, on CE Marking and the Medical Devices Directives, at the following UK locations: Pontypridd (November 14th); Leeds (November 28th); and Maidenhead (December 7th, 1995). It aims to guide medical device manufacturers on the impact of the directives, including LVD, EMC and Machinery Directives. For further details, contact: Lorraine Balch, BSI Product Certification. Tel: +44 (1908) 312636.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.